OBJECTIVES: To evaluate in-hospital adverse events associated with typical and atypical antipsychotic medications (APMs) after cardiac surgery. DESIGN: Retrospective cohort study. SETTING: Nationwide inpatient database, 2003 to 14. PARTICIPANTS: Individuals (mean age 70) newly treated with oral atypical (n = 2,580) or typical (n = 1,126 APMs) after coronary artery bypass grafting or valve surgery (N = 3,706). MEASUREMENTS: In-hospital mortality, arrhythmia, pneumonia, use of brain imaging (surrogate for oversedation and neurological events), and length of stay after drug initiation RESULTS: In the propensity score-matched cohort, median treatment duration was 3 days (interquartile range (IQR) 1-6 days) for atypical APMs and 2 days (IQR 1-3 days) for typical APMs. There were no large differences in in-hospital mortality (atypical 5.4%, typical 5.3%; risk difference (RD) = 0.1%, 95% confidence interval (CI) = À2.1 to 2.3%), arrhythmia (2.0% vs 2.2%; RD = 0.0%; 95% CI = À1.4 to 1.4%), pneumonia (16.1% vs 14.5%; RD = 1.6%, 95% CI = À1.9 to 5.0%), and length of stay (9.9 days vs 9.3 days; mean difference = 0.5 days, 95% CI = À1.2 to 2.2). Use of brain imaging was more common after initiating atypical APMs (17.3%) than after typical APMs (12.4%; RD = 4.9%, 95% CI = 1.4-8.4).
D
elirium affects 35-60% of individuals after cardiac surgery. It is associated with greater mortality, poorer postoperative outcomes, and higher healthcare costs. [1] [2] [3] [4] Approximately 10-50% of individuals with delirium develop agitation [4] [5] [6] that often requires antipsychotic medication (APM). The American Geriatrics Society Clinical Practice Guideline recommends use of the lowest effective dose of an APM for the shortest duration, acknowledging its unclear effectiveness and numerous harms, including effects on the central nervous system (e.g., oversedation, extrapyramidal symptoms), cardiovascular system (e.g., QTc prolongation, arrhythmia), and pneumonia. 7 Current evidence on the safety of APMs mainly comes from studies of long-term use in community-dwelling older adults and nursing home residents with dementia. These studies have consistently shown that typical APMs confer a higher risk of mortality than atypical APMs when used to treat behavioral symptoms of dementia, [8] [9] [10] [11] [12] [13] [14] but little is known about the safety of APMs when used for a short duration to treat delirium-related agitation in hospitalized individuals. Several randomized controlled trials of APMs to treat delirium were underpowered to examine adverse clinical events (sample size < 100). 7 Although a few small observational studies in the medical inpatient setting found no difference between adverse events associated with APMs and those associated with no use, [15] [16] [17] there are a paucity of safety data in individuals undergoing cardiac surgery who may be susceptible to cardiac and other postoperative adverse events that have been linked to APMs. In addition, most untreated individuals have hypoactive delirium, for which APMs are not indicated, and they are already at greater risk of adverse events. Thus, comparing treated with untreated individuals with delirium may be less useful to clinicians who are considering an APM to treat delirium-related agitation.
The objective of the current study was to investigate in-hospital adverse events associated with short-term use of oral atypical and typical APMs in a national inpatient database of individuals who underwent cardiac surgery. It was hypothesized that individuals treated with oral atypical APMs would have a lower risk of in-hospital mortality, arrhythmia, pneumonia, neurological events, and prolonged hospitalization than those treated with oral typical APMs after cardiac surgery.
METHODS

Data Source and Study Population
This was a retrospective cohort study using the Premier database, which contains complete billing and coding information for approximately 20% of hospital discharges in the United States. The database includes all inpatients treated at participating hospitals and contains information on demographic characteristics, admission characteristics, discharge diagnoses and status, date-stamped log of all billed items (e.g., medications, procedures, diagnostic tests), and hospital-level characteristics. Data are routinely audited, reconciled, and validated to ensure that the use of supplies and hospital resources is within an acceptable range. The database has been used to study the effectiveness and safety of medications in the perioperative setting. [18] [19] [20] [21] The Partners institutional review board approved this research.
Although delirium is undercoded in administrative databases, delirium constitutes a majority of indications for APM initiation in the hospital. 22, 23 Thus, it was assumed that individuals who did not receive APMs on admission and were newly treated with the drugs after cardiac surgery had postoperative delirium with agitation requiring pharmacological intervention. The eligible cohort consisted of 205,274 adults who underwent coronary artery bypass grafting (International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes 36.1x) or valve replacement (ICD-9 diagnosis codes 35.2x) between hospital Days 2 and 7 from January 1, 2003, to December 31, 2014. Because outpatient medications are not recorded in the database, at least one hospital day before surgery was required to obtain preoperative drug exposure. Analysis was restricted to individuals who underwent surgery within seven hospital days, because those with prolonged hospitalization before surgery (operated after seven hospital days) might have a different risk of adverse events. To exclude chronic APM users, individuals who had received APMs before surgery (n = 5,273) or had a diagnosis of schizophrenia or bipolar disorder (n = 1,560) were excluded. Those who never received APMs (n = 264,817), started two or more different drugs on the same day (n = 1,330), or received parenteral drugs (n = 11,386) were also excluded. The latter two excluded groups generally represent those with greater severity of illness. The study cohort, therefore, included 3,706 individuals who initiated a single oral APM after cardiac surgery (Figure 1 ).
Exposure and Study Outcomes
Daily exposure to atypical and typical APMs was determined using charge codes (see the generic names in Table S1 ). Total APM dose administered on the day of initiation was converted to chlorpromazine-equivalent dose 24 ; low dose was defined as a chlorpromazine-equivalent dose of 100 mg/d or less (median dose of typical APM group), which corresponds to haloperidol 2 mg/d or less, olanzapine 5 mg/d or less, quetiapine 75 mg/d or less, or risperidone 2 mg/d or less.
The outcomes were in-hospital mortality and clinical adverse events related to APMs, defined using a combination of discharge diagnoses and date-stamped charge codes for medications, procedures, and diagnostic tests that appeared after initiation of APMs: arrhythmia (cardiopulmonary resuscitation or cardioversion); pneumonia (discharge diagnosis of pneumonia, ICD-9 diagnosis codes 481-486 and 507 plus initiation of ≥2 antibiotics); use of brain imaging (brain computed tomography or magnetic resonance imaging) as a surrogate marker of oversedation, altered mental status, and other neurologic events; and length of stay after initiation of APMs. The current validation study based on medical record review (Appendix S1) that 81% of individuals who underwent brain imaging after cardiac surgery had indications of altered mental status or neurological abnormalities (Table S2) . Follow-up began on the day after APM initiation and ended on the discharge day, regardless of treatment duration (analogous to intention-to-treat analysis).
Measurement of Individual-and Hospital-Level Covariates
Individual-level, procedure-related, and hospital-level characteristics were considered (Table S3 ). The Romano modification of the Charlson Comorbidity Index was created using the discharge diagnosis information. 25 All procedures and medications were measured from admission date until the day before APM initiation.
Statistical Analysis
Propensity score matching was used to adjust for differences in individual-and hospital-level characteristics between treatment groups. Propensity to receive atypical APMs as opposed to typical APMs was estimated using logistic regression. The logistic models included all individual-and hospital-level variables listed above, as well as number of days between surgery and drug initiation to make the onset of delirium-related agitation comparable between the treatment groups. One-to-one nearest-neighbor matching was performed using a caliper that corresponded-0.2 of the standard deviation of the logit propensity score. 26 The covariate balance between the treatment groups was evaluated using standardized mean differences before and after matching. An absolute standardized mean difference less than 0.1 was considered an appropriate level of balance.
The main analysis was to compare risk differences (RDs) and risk ratios (RRs) with their 95% confidence intervals (CIs) for in-hospital mortality, arrhythmia, pneumonia, and use of brain imaging associated with initiation of atypical APMs with those of initiation of typical APMs in the matched cohort. Binomial regression was used for RDs, modified Poisson regression for RRs (which avoids convergence problems of log binomial regression), 27 and linear regression for the mean difference in length of stay after drug initiation. Generalized estimating equations with robust standard errors were used to account for clustering of individuals within hospitals. 28 As secondary analyses, whether the comparative safety profile differed according to age (<65, 65-74, ≥75), comorbidity burden (Charlson Comorbidity Index ≤4, >4), and level of care (ward, intensive care) at the time of APM initiation was examined. Because adverse events that occurred several days after treatment initiation may not be attributable to the drug itself, events that occurred within 3, 5, and 7 days of initiation were examined. Comparisons were made according to dose categories (low-dose atypical APMs vs low-dose typical APMs, high-dose atypical APMs vs high-dose typical APMs) and pairwise comparisons between haloperidol (reference group) and olanzapine, quetiapine, and risperidone. Propensity scores were estimated for each pairwise comparison using haloperidol as the reference, and one-to-one nearest-neighbor matching was performed as in the main analysis. In addition, several sensitivity analyses were conducted to test robustness of the results to several assumptions made in outcome definition, analytical approaches, and unmeasured confounding (Appendix s2). All analyses were performed in SAS version 9.3 (SAS Institute, Inc., Cary, NC) and R version 3.2.3. Two-sided P < .05 was considered statistically significant.
RESULTS
Use of APMs After Cardiac Surgery
The proportion of individuals who were newly treated with any APM after cardiac surgery was 5.8%. Treated individuals had higher in-hospital mortality (6.3%) than untreated individuals (2.7%). Of 3,706 individuals treated with an oral APM, 2,580 (69.6%) received an atypical APM (3 most common exposures were quetiapine 50.2%, risperidone 22.5%, and olanzapine 21.0%), and 1,126 (30.4%) received a typical APM (haloperidol 84.5%, mesoridazine 9.7%). Treatment was initiated within a median of 4 days after surgery (interquartile range 2-8 days).
The 2,580 individuals treated with atypical APMs were younger and more likely to be black and undergo valve surgery than the 1,126 treated with typical APMs (Table 1) . Those receiving atypical APMs were more severely ill and had a greater comorbidity, as evidenced by a greater Charlson Comorbidity Index, longer duration of critical care and ventilation support, and greater use of blood transfusion and dialysis. They were more likely to be treated at larger, nonteaching hospitals with higher procedure volume and in the south. 
Adverse Events Associated with Atypical and Typical APMs
In the 832 propensity score-matched pairs, the differences in individual-and hospital-level characteristics were minimal (Table 1) . Median duration of treatment was 3 days (interquartile range (IQR) 1-6 days) for atypical APMs and 2 days (IQR 1-3 days) for typical APMs; 5.0% switched to a different class and 10.6% to parenteral drugs.
Before propensity score matching, adverse events were more common in individuals treated with atypical APMs than those treated with typical APMs (Table 2) . After matching, there were no significant differences between the treatment groups in terms of in-hospital mortality (5.4% vs 5.3%; RD = 0.1%, 95% CI = À2.1 to 2.3; RR = 1.02, 95% CI = 0.68-1.54), arrhythmia (2.0% vs 2.2%; RD = 0.0%, 95% CI = À1.4 to 1.4; RR = 1.00, 95% CI = 0.51-1.98), pneumonia (16.1% vs 14.5%; RD = 1.6%, 95% CI = À1.9 to 5.0; RR = 1.11, 95% CI = 0.89-1.38), and length of stay (9.9 days vs 9.3 days; mean difference 0.5 days), although these differences were imprecisely estimated because of the small sample size and low event rates, and the possibility of modest differences in these events cannot be excluded. Greater use of brain imaging was found after initiation of atypical APMs (17.3%) than of typical APMs (12.4%) (RD = 4.9%, 95% CI = 1.4-8.4; RR = 1.40, 95% CI = 1.10-1.78). This suggests that, in every 20 individuals treated with atypical APMs instead of typical APMs, one will suffer from oversedation or adverse neurological events requiring brain imaging.
Secondary Analyses
No meaningful difference was found according to age, comorbidity burden, level of care, or follow-up time (Tables 3 and S4) , with a few exceptions; the association between atypical APMs and use of brain imaging seemed somewhat stronger in individuals aged 75 and older (RD = 8.5%, 95% CI = 3.0-13.9; RR = 1.84, 95% CI = 1.23-2.76) and in individuals in the intensive care unit (RD = 8.6%, 95% CI = 3.0-14.2; RR = 1.56, 95% CI = 1.16-2.09). Individuals treated with low-dose APMs (RD = 4.7%, 95% CI = 0.1-9.3; RR = 1.41, 95% CI = 1.01-1.98) were more likely to undergo brain imaging and those who received quetiapine were more likely to undergo brain imaging than those who received haloperidol (RD = 5.0%, 95% CI = 1.0-8.9; RR = 1.43, 95% CI = 1.07-1.92) ( Table S4) . Because of limited sample size, it was not possible to determine whether this association differed from that for olanzapine or risperidone.
Sensitivity Analysis
When the neurological event was redefined as use of brain imaging without a discharge diagnosis of stroke or transient ischemic attack, the association was slightly stronger (RD = 4.2%, 95% CI = 1.5-6.9; RR = 1.62, 95% CI = 1.18-2.21), which supports the presence of adverse neurological effects of atypical APMs other than stroke.
The results of alternative analytical approaches, such as conditional logistic regression, restriction to individuals who received two or more consecutive days of initial APM class, and Cox regression, were similar to those from the main analysis (Table S5 , Analyses 2-4). The as-treated analysis produced inconclusive estimates because of the small number of events (Analysis 5). Excluding outcomes that occurred within 1 to 2 days did not meaningfully change the association (Analyses 6 and 7). The sensitivity analysis for unmeasured confounder suggests that a prevalence difference greater than 30% or an association between the confounder and outcome greater than 3.0 would be needed to change the RRs by more than 10% ( Figure S1 ).
DISCUSSION
In a national sample of older adults who newly received an APM after cardiac surgery, no large difference was found in in-hospital mortality, arrhythmia, pneumonia, or length of stay between those treated with atypical and typical APMs, although the low event rates did not preclude modest differences in the risk of adverse events. Nonetheless, there was a possible adverse effect of atypical APMs on the central nervous system (e.g., oversedation), as reflected by greater use of brain imaging.
There is abundant evidence of the harms of long-term APM treatment. Several observational studies [8] [9] [10] [11] [12] [13] [14] and metaanalyses of randomized controlled trials 29, 30 have shown that long-term treatment is associated with greater mortality in older adults with dementia. In these studies, mortality risk was higher immediately after drug initiation and attenuated over time. 10, 11 Typical APMs conferred higher risk of mortality than atypical APMs [8] [9] [10] [11] [12] [13] [14] ; quetiapine seemed to have the lowest risk. 11, 12 Excess mortality from cardiovascular, respiratory, and infectious causes associated with typical APMs partly explained the higher risk. 14 Hospitalized older adults undergoing cardiac surgery are less frail than community-dwelling or institutionalized older adults who need APMs for dementia-related behavioral problems. Treatment is usually short (several days) when APMs are used to treat delirium-related agitation.
Because of differences in population characteristics and treatment duration, the frequency and effect of adverse events may differ in individuals undergoing cardiac surgery from in individuals with dementia. In the current study, atypical APMs were used more frequently (69.6%) than typical APMs (30.4%) and more likely to be used in sicker individuals, as reflected by higher disease burden (Table 1) and risks of adverse events before propensity score matching (Table 2 ). These observations suggest that physicians presume that atypical APMs are safer than typical APMs, but there is little information on the safety of short-term APM treatment. A few observational studies conducted in hospitalized individuals had a sample that was too small to allow comparison between different APMs. [15] [16] [17] In a single-center study of individuals with delirium in cardiac care unit not undergoing surgery, treatment with haloperidol or quetiapine was not associated with mortality and QTc prolongation compared with no use. 17 Considering that APMs are not indicated for hypoactive delirium, the analysis of APM use vs. no use may reflect the comparison of hyperactive vs hypoactive delirium. Although the current study did not include untreated individuals, the risk of adverse events in the population treated with oral APMs was higher than the previously reported risk of mortality (3.1%), 31 pneumonia (3.1-4.5%), 32, 33 and arrhythmia (1.7%) 34 in individuals undergoing cardiac surgery. Shortterm use of typical APMs does not appear to confer a greater risk of in-hospital mortality and arrhythmia than atypical APMs in these individuals. Although the indications for brain imaging were not available in the Premier database, the validation study based on medical record review suggests that it is a reliable surrogate for altered mental state and adverse neurological events. Unless physicians who had a preference for atypical APMs were more likely to obtain brain imaging, it is likely that greater use of brain imaging after initiating atypical APMs than after typical APMs was because of the immediate negative effect of atypical APMs on the central nervous system (e.g., oversedation) through their antihistamine properties. The differential associations for individual atypical APMs vs haloperidol (Table S4 ) with use of brain imaging make it less likely that a general prescribing preference for atypical APMs was associated with a lower threshold for ordering brain imaging. Quetiapine has a more-sedating profile than other drugs, which might explain this association. The possibility of administering an APM to sedate an individual for brain imaging is also unlikely, because the sensitivity analyses restricted to individuals who received APMs for two or more consecutive days and excluding the events occurring within 1 to 2 days of initiation showed persistent associations. The positive association between atypical APMs and brain imaging seemed slightly stronger in the low-dose comparison (RR = 1.41, 95% CI = 1.01-1.98) than in the high-dose comparison (RR = 1.28, 95% CI = 0.85-1.93). Although the smaller sample size receiving high-dose APMs was, in part, responsible for lack of statistically significant difference, it may be that difference in the risk of sedation between atypical and typical APMs used in high doses is less pronounced. In addition, APMs may cause aspiration pneumonia by impairing swallowing function. 35 A metaanalysis of pneumonia risk showed a pooled odds ratio of 1.68 for typical APMs and 1.98 for atypical APMs. 36 The current study was underpowered to detect a small risk difference in pneumonia according to APM class.
These results are generally consistent with the risks of adverse events reported in randomized controlled trials of APMs (Table S6) . Although the risk varied widely according to study population (e.g., critical care, inpatient, postoperative settings), sedation was a common adverse event that seemed to occur more often with atypical APMs (quetiapine, 5-42%; olanzapine, 0-33%; risperidone, 15-29%) than typical APMs (haloperidol, 0-29%). The sedating effect is an important consideration in treatment of delirium-related agitation because APMs may simply convert hyperactive delirium to hypoactive delirium without improving clinical outcomes. A metaanalysis of randomized controlled trials showed no difference in in-hospital mortality and length of stay between APM classes. 37 Trial evidence on arrhythmia and extrapyramidal symptoms was heterogeneous; pneumonia was rarely reported.
Strengths and Limitations
A national inpatient database was analyzed, which enhances generalizability. To minimize confounding, restriction was applied in the form of active comparator and new-user design 38 and propensity score matching. Restriction is superior to statistical adjustment in reducing confounding according to health status and frailty. 39 This study also has important limitations to consider. Despite use of a national database, the analyses did not have sufficient power to detect modest associations, and the 95% CI of the estimate for in-hospital mortality contained the estimates from studies of long-term treatment in older adults with dementia. Thus, it is not possible to conclude that safety profiles of these drugs in hospitalized individuals are different from those in older adults with dementia. Because most individuals were treated for a median of 2 to 3 days, it was not possible to evaluate the risk associated with longer treatment. In the Premier database, the onset of nonfatal adverse events was determined based on date-stamped charges for services (e.g., antibiotics, brain imaging). If there was a lag time between the onset of adverse events and use of these services, the adverse events might have preceded APM use. The sensitivity analysis showed that the potential lag time of 1 to 2 days was unlikely to change the main results.
It was assumed that APMs were used for deliriumrelated agitation. In hospitalized older adults, the most common indication of APM initiation was delirium (65-83%). 22, 23 Considering that delirium is poorly documented in clinical notes (32-56% against a criterion-standard assessment), 40 it is likely that use of APMs for indications unrelated to delirium is uncommon. Although the use of brain imaging had a positive predictive value of 0.81 for altered mental status and neurological events in a medical record review, this estimate was based on the physician practice in a large academic health system and might not be generalizable to other hospitals. Outcome definitions based on discharge diagnosis and charge codes have high specificity and moderate sensitivity (e.g., sensitivity 55-70%, specificity 99% for pneumonia). 41 Accordingly, not every outcome event may have been captured, which results in underestimation of RD estimates. As long as the imperfect detection of outcome events was non-differential between individuals treated with typical APMs and with atypical APMs, the RR estimates should have been minimally biased. Although the severity of delirium and illness were unavailable in the Premier database, a large imbalance (prevalence difference >30%) between the treatment groups or a strong independent effect (RR > 3.0) on outcomes is unlikely in an active-comparator study that adjusted for an extensive list of covariates. Finally, in the Premier database, which contains only inpatient information, it was not possible to examine persistent APM use before admission or adverse events after discharge.
CONCLUSIONS
This analysis of a national sample of individuals undergoing cardiac surgery suggests that short-term use of oral typical APMs may cause less sedation and adverse neurological events, without much greater in-hospital mortality, arrhythmia, pneumonia, or length of stay, than oral atypical APMs, but because of the low event rates, modest but potentially clinically important differences in adverse events, including mortality, cannot be excluded. The findings, therefore, need to be interpreted with caution, particularly given the existing literature associating typical APMs with greater risk of death in other settings. More research in a larger sample of individuals undergoing different surgeries is needed to confirm these findings. BTB is supported by Grant K08HD075831 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. ERM was funded by Grants R01AG030618 and P01AG031720, and Mid-Career Investigator Award K24AG035075 from the National Institute on Aging. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
ACKNOWLEDGMENTS
Author Contributions: Kim: Study design, data analysis and interpretation, preparation and revision of manuscript. Huybrechts, Patorno, Park, Abdurrob, Bateman: Study design, data interpretation, revision of manuscript for intellectual content. Marcantonio: Data interpretation, revision of manuscript for intellectual content. Levin: Statistical analysis, revision of manuscript for intellectual content.
Sponsor's Role: The funding sources did not have any role in study design; collection, analysis, or interpretation of data; writing of the report; or the decision to submit for publication.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article: Appendix S1. Medical Record Review to Evaluate Indications for Brain Imaging After Cardiac Surgery Appendix S2. Statistical Analysis for Sensitivity Analyses Table S1 . List of Antipsychotic Medications Figure S1 . Influence of unmeasured confounders in comparing atypical and typical antipsychotic drugs after cardiac surgery
Please note: Wiley-Blackwell is not responsible for the content, accuracy, errors, or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.
